Parents struggling with inflated baby formula prices and misleading health claims
Jess Brown-Fuller, a Liberal Democrat MP and chairwoman of the All Party Parliamentary Group (APPG) on Infant Feeding, highlighted how new parents are particularly vulnerable.
She asserted that firms are "exploiting a legal loophole" to circumvent advertising regulations, further alleging that discounted product offerings to hospitals create the misleading impression of an NHS endorsement.
The report noted formula manufacturers hiked prices by an average of 25 per cent in the two years leading up to November 2023, with costs remaining at near-record levels.
This occurs despite the common parental misconception that a higher price tag equates to a more nutritious product, when regulations mandate all formula on the market must be nutritionally equivalent.
Ms Brown-Fuller told the PA news agency: 'There are parents who believe that by buying the more expensive formula, they are supporting their child's feeding or growth or potential more when actually all of those milks are nutritionally equivalent.'
There are even reports of parents buying more expensive formula but using fewer scoops per bottle to try and make it last longer, which Ms Brown-Fuller branded 'dangerous'.
These parents are doing what they think is best for their children, she said, when in reality there is 'no difference' between the £14 tub and £7 tub of formula.
The Liberal Democrat noted that companies will use their packaging to 'imply a nutritional superiority', with phrases like 'nutritionally complete' or 'supports a healthy immune system'.
She asked: 'Where is the evidence that suggests that that formula is in any way a boost to an infant's immune system above any others?'
Meanwhile, other formulas will write 'with added…' and name ingredients like Omega 3, certain vitamins, or iron.
Ms Brown-Fuller said: 'It has to have a certain number of nutrients in it anyway. And anything that is additional potentially shouldn't be in there because they are working around a very strict compliance code.'
She explained: 'They wouldn't be able to make these bold claims if they were a medication but, because it's a food, it's a source of nutrition, they're not held to the same standards.'
Meanwhile, it is illegal to advertise newborn formula in the UK but firms are allowed to advertise follow-on milk for babies that are six months and older.
This is because World Health Organisation (WHO) guidance is that breast milk should be the main source of nutrition for all infants until they are six months old, and a lack of advertising regulation is linked to lower breastfeeding rates.
Ms Brown-Fuller said: 'There is a direct correlation between countries that have no regulation around formula marketing and drastic reductions in breastfeeding.
'So that is why the Government did introduce regulation around advertising of formula milk because the numbers of breastfeeding mothers was dramatically reducing.'
The UK scores just 48 out of 100 overall on a range of infant-feeding metrics, according to the World Breastfeeding Trends Initiative.
However, to get around these regulations, formula companies advertise for their follow-on milk and 'make all their packaging look exactly the same to anybody that was just perusing the shelves'.
The Chichester MP said: 'They're exploiting a legal loophole, because it is a legal loophole, but they've totally blurred the lines through similar branding.'
Another form of 'exploitative' marketing, she argued, is that formula companies will sell their formula into healthcare professional environments like maternity units or neonatal units for a hugely reduced price.
Purchase habits show strong brand loyalty when it comes to formula, with parents rarely switching brands once they have introduced a particular one to their baby.
It is also argued that brand presence in a healthcare setting gives the 'fake impression of an NHS endorsement'.
Ms Brown-Fuller told PA: 'They know that if they get the parents to use that in a hospital setting, the likelihood is that that is the formula they will then use when they go home.'
The CMA has put forward 11 recommendations to address these issues, aiming to strengthen labelling and advertising rules, better inform parents to make choices in retail environments and to eliminate brand influence in healthcare settings with standardised packaging.
Department of Health and Social Care spokesperson said: 'As part of our Plan for Change, we're determined to ensure every child has the best start to life.
'There are many benefits of breastfeeding but for those mothers that cannot or choose not to breastfeed, it is vital parents can access infant formula that is affordable and high quality. Families should not be paying over the odds to feed their babies.
'We are working closely with the devolved governments to carefully consider the CMA's recommendations and will respond fully in due course.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
8 minutes ago
- The Sun
Warning after woman left with agonising blisters from picking blackberries which could have KILLED her
BRITS have been warned after a woman was left with 'agonising' blisters having gone blackberry picking which could have killed her. Nature lover Sue Harries suffered extreme pain after a toxic plant left her covered in a horrifying rash. 2 2 The 53-year-old was collecting the berries near her home in Wales when her arm brushed nearby hogweed and was touched by its toxins. Sue didn't spot anything wrong straight away but was later covered in blisters and in "agony" as the wounds developed. A rash came up around two hours after touching the toxic plant and later spread all up her arm and onto her back. Sue said that two weeks after the hogweed horror she is still reeling from the affects of the plant - and was told that if she had eaten blackberries touched by the plant her airways could have closed. She said: "Even now, my arm is burning, literally burning. I didn't feel anything at the time, I must have just brushed past it. "I went to my doctor a week later because I've been in and I honestly mean it, I've been in agony with it. "I just want people to know about it because I never knew it was toxic and I wouldn't want anyone else to go through this." Sue has now been told to keep her arm out of the sun for at least four months and ensure she wears factor 50 sun cream or keep her affected limb covered for at least the next five years. Sue, of Mayals, Swansea, brushed against the hogweed - which is officially known as Heracleum sphondylium - and has toxic sap, stems, leaves and fruit which can leave lasting damage. In June last year, Jenson Price was left with agonising blisters when he brushed past giant hogweed. Boy, 9, left with horrific burns and blisters after brushing past 'Putin' toxic plant while playing football in the park The nine-year-old had come into contact with the plant while running to fetch the football during the kickabout with his friends in Ryhope Park, Sunderland. The toxic sap from the plant increases the sensitivity of the skin to sunlight, often leading to burns - and sometimes blindness. While in June 2022, Ella, a 22-month-old toddler, was rushed to hospital having touched giant hogweed. Ella was taken to two hospitals, North Tees and James Cook, but doctors and medics were unable to determine what had caused such injuries. The tot required intensive treatment, doctors had to burst her blisters, carve away her dead skin, and finally bandaged her hands. A similar incident occurred the same year when Chavana Neuweg's six-year-old daughter suffered poisoning from a hemlock plant growing in their garden. The young child suffered a severe rash and trouble breathing, resulting in a trip to the hospital. Dog owners have also been warned about the dangers the plant poses to our furry friends. Hogweed can tower up to 16ft tall, according to the RHS, with long green stems with purple blotches, huge branches of small white flowers and green leaves. Mike Duddy, of the Mersey Basin Rivers Trust, previously said: "Giant hogweed was without a shadow of a doubt, the most dangerous plant in Britain". It is native to the Caucasus but was introduced to Britain as an ornamental plant in 1817, and its spread has now gotten out of control. Everything you need to know about giant hogweeds Giant Hogweed may look impressive but any contact with the sap of this plant can cause serious injury, particularly to your skin. What does Giant Hogweed look like? When fully grown, giant hogweed is aptly named. The plant can grow up to 25ft tall, with long green stems, purple blotches, and huge branches of small white flowers and large green leaves. The plant's flower heads bloom in June and July and can reach up to 2ft across. Giant hogweed can be mistaken for other plants such as cow parsley, cow parsnip, Queen Anne's Lace or elderberry as the flowers look similar. Their size when fully grown is very helpful for identifying the harmful crop. Why does Giant Hogweed cause rashes, burns and blisters? Giant hogweed stems have fine needle-like hairs that can cause extreme irritation. While the sap in giant hogweed contains a chemical called furanocoumarins. When this toxin comes into contact with the skin, it binds with DNA in skin cells, causing them to die. The sap reacts with the melanin in your skin and removes protection that patch has from UV light, causing photosensitivity (where the affected area becomes highly sensitive to sunlight), resulting in nasty burns, lesions and blisters. Those burns can last for several months and, even once they've gone, skin can remain scarred and sensitive to sunlight for years to come. If the hairs of the giant hogweed plant or its sap come into contact with your eyes, they can even cause temporary or even permanent blindness in severe cases. How do I treat burns from Giant Hogweeds? The NHS website advises that if you come into contact with giant hogweed and you get a burn, you should wash the affected area with soap and water and then cover it, keeping it out of natural or artificial light. If blisters appear, do not burst them! If the blisters are extensive, seek medical attention. Should you get sap in your eye, flush the eye with a large amount of water and seek medical attention. If you begin to feel unwell after contact with giant hogweed, speak to your doctor. Ensure you thoroughly and quickly wash the clothes you were wearing when you came into contact with the plant. And if you're concerned that a child has come into contact with, or ingested giant hogweed, seek medical attention immediately
The Sun
8 minutes ago
- The Sun
Major change to driving tests that impacts ALL learners to be rolled out in months – what it means for you
A MAJOR change to driving tests will impact all learners across the UK and is set to be rolled out in just months. Learner drivers sitting their driving theory test will soon need to brush up on their CPR skills in an effort to save thousands of lives every year. 1 Driving theory tests will include added questions on CPR and defibrillators from early next year, the Driver and Vehicle Standards Agency (DVSA) has said. Theory test questions will be expanded to include "enhanced" CPR content. While questions on external defibrillators, or AEDs, will be added for the first time. Theory test candidates will therefore need to brush up on their CPR techniques including proper placement and compression rates as well as how to use an AED. The changes are a bid to ensure drivers know how how to use a defibrillator and how to respond in emergencies. It is hoped that new learners will be equipped with life-saving skills through the enhanced questions with 2.4 million theory tests taken each year. For example, one new theory test question relates to the correct depth to push down during CPR. Mark Winn, DVSA Chief Driving Examiner, said: "Part of being a safe and responsible driver is knowing what to do in an emergency – how to step in and make a real, life-saving difference. "Learning CPR and how to use an AED is a very simple skill and adding this into the official learning resource is a great way for DVSA to support the drive to raise awareness." According to the DVSA, drivers are often first on the scene when someone suffers a cardiac arrest. Watch Tesla test self-driving cars on London streets as it passes famous landmarks More than 40,000 out-of-hospital cardiac arrests occur every year in the UK but fewer than 1 in 10 people survive. But if CPR is administered and an AED used within 3 to 5 minutes of collapse, survival rates can reach as high as 70 per cent. Otherwise, every minute that passes reduces those chances by up to 10 per cent. Life-saving CPR skills may be required in a range of scenarios on the road. Trauma or shock resulting from a collision could cause a cardiac arrest or a driver could have a cardiac arrest behind the wheel causing a road traffic incident. Motorists may also be required in roadside emergencies if someone has collapsed on the roadside. For example, runners may experience a sudden cardiac arrest and elderly people or those with heart conditions could also collapse in public spaces. And incidents could also occur at service areas including motorway services, petrol stations and car parks Intervention can be crucial to saving lives before professional help arrives on the scene. The theory test changes are a result of collaboration between the DVSA and organisations such as Save a Life programmes in Wales, Scotland and Northern Ireland in addition to Resuscitation Council UK. Learner drivers must first take a theory test and hazard perception test before they can book their practical driving test. To pass the theory test, learners must achieve 43 out of 50 correct answers. The DVSA also announced in May that three major practical driving test changes were to be trialled across the UK to speed up exams for thousands of learners.
Daily Mail
35 minutes ago
- Daily Mail
SMALL CAP IDEA: Ketamine drip therapy firm is taking on alcoholism
As the dust settles on its successful takeover of Awakn Life Sciences, investors are starting to appreciate the potential of Solvonis Therapeutics. Yet the current valuation of £23million doesn't tell the full story. Or perhaps it tells its own tale: that the Brits are blinkered, even oblivious to a story unfolding on the other side of the Atlantic that has real and positive implications for Solvonis. More on this later. First, it's probably worth refreshing ourselves as to what the company is and does. Quite simply, it is a biotech company that is developing potential treatments for illnesses such as alcohol abuse, post-traumatic stress disorder, and depression, where innovation and treatment options are sorely lacking. And they have been for a number of decades. It has four programmes, one in phase III, which on a more progressive and capital-deep market such as Nasdaq would in and of itself justify at least one additional nought to Solvonis' market capitalisation. Again, more on this later. Its lead drug is SNV-001, an experimental treatment being tested in advanced clinical trials for people with severe alcohol use disorder (AUD). It combines two approaches: a carefully controlled dose of ketamine (a dual anaesthetic and painkiller medicine that affects certain brain receptors) given by drip, and a course of cognitive behavioural therapy, or CBT, designed to specifically help prevent relapse. The aim is to see if using these together can help people stay off alcohol more effectively than either treatment alone. Early trial results for SNV-001 have been encouraging. In phase II testing, people given the treatment had 50 per cent fewer heavy drinking days compared to those who received a placebo. Even more striking, on average 86 per cent of participants stayed off alcohol for six months after treatment, while only 2 per cent had managed this before joining the trial. The results were so good that the UK Department of Health through the National Institute of Health and Care Research are co-funding the trial. Looking ahead, the company plans to seek what is called a mixed-full approval in both the UK and EU, which could mean up to 10 years of market exclusivity if successful. Its second asset is where the hidden value resides and where, I would contend, the UK investing public just isn't recognising the upside. Called SVN-002, it is an experimental treatment being developed in the much larger US alcohol addiction treatment market It uses esketamine, closely related to ketamine, and, crucially, a compound already being used in Johnson & Johnson's new blockbuster, Spravato, in nasal form, to combat treatment-resistant depression. Top marks if you made the link. Don't worry if you didn't; but pay attention at the back! So alike are the two compounds that Solvonis last month kicked off a process designed to provide scientific 'bridging' data linking SVN‑002 to Spravato. By referencing the existing drug, Solvonis aims to pursue the 505(b)(2) regulatory pathway, a route that allows companies to rely on existing data to streamline approval processes. Not only this, the company also hopes SVN-002 will be eligible under the same reimbursement codes as Spravato, potentially saving significant time and cost. Now, here's the eyes-on-stalk moment. Spravato is already generating annual revenues of more than $1billion and analysts believe this figure could actually peak at $5billion. However, its addressable market is a couple of million Americans with severe depression. Contrast this with the estimated 22 million people in the States who struggle badly with alcohol. As they say in the States, you do the math(s). American investors have not been slow to cotton on. Companies listed across there paddling in similar, or adjacent, pools, the likes of Atai Life Sciences, MindMed, GH Research and Compass Pathways, have been in lift-off mode. Meanwhile, pharma giant Abbvie is reported in the US business press last week to be preparing a $1billion offer for a privately owned-US peer of Solvonis, a company called Gilgamesh Pharmaceuticals. In other words, real buzz around the sector in the States that has so far been absent here in the UK, which is also reflected in valuations stateside, which are orders of magnitude larger than Solvonis. Atai, for example, has programmes barely emerged from phase I and carries a market capitalisation of more than $800million. That reflects America's greater understanding of not just biotech, but the potential of this new emerging area of treatment. Value inflexion points for companies such as Solvonis tend to come at the end of clinical studies – phase II usually, but also phase III. This is when large pharma is sufficiently emboldened to invest in the expensive process of follow-on studies, and/or pouring tens of millions of dollars into gaining regulatory sign-off. A licensing agreement of this type not only provides third-party validation of the work to date, it comes with financial kickers such as upfront and milestone payments. We already know that Solvonis has drafted in Pharma Ventures, a specialist in partnership and alliances of the sort outlined above, to shop SNV-001. So, one can safely assume conversations are taking place. It will be interesting to track the role in negotiations played by Solvonis chair Dennis Purcell. He is also a director of IGI, which recently cut a $1.9 billion deal with AbbVie, with $700million of that upfront. Okay, this was in the oncology arena, but Purcell has first-hand experience of going toe-to-toe with big pharma. And this will be crucial when talks hit the nitty-gritty phase. A recent research note penned by the team at Singers used the net present value of Solvonis' two clinical stage assets, allied to what it calls a 'risk-adjusted patient-based forecast', to come up with a 1.6p price target. So, what does all this mean? Well, it suggests Solvonis' share price of 0.37p may not reflect the company's true potential.
